Sen­ti Bio’s Phase 1 CAR-NK da­ta; Allink rais­es $42M

Plus, news about Cy­to­ki­net­ics, Ther­at­e­ch­nolo­gies, Kiso­Ji Biotech­nol­o­gy and XO­MA Roy­al­ty:

Sen­ti Bio touts ear­ly Phase 1 CAR-NK da­ta, stock soars: Two of three pa­tients who …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER